Alphanine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Alphanine market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of hemophilia, investments in research and development, emphasis on prophylactic treatments, a strong pipeline of treatments, and global healthcare investments.

Growth during the market's forecast period is driven by factors such as emerging markets, early diagnosis and advanced treatment options, government initiatives and healthcare policies, approval of gene therapies for hemophilia treatment, and an increase in life expectancy. Key trends during this period include the development of recombinant therapies, advancements in gene therapy, personalized treatment approaches, improvements in plasma collection and processing, and technological innovations in treatment delivery.

The increasing prevalence of hemophilia is expected to drive the growth of the alphanine market in the future. Hemophilia is a rare, inherited bleeding disorder where blood does not clot properly due to a deficiency or absence of clotting factors, specifically VIII and IX. The rise in hemophilia prevalence can be attributed to factors such as better diagnosis, increased awareness, improved reporting, and genetic inheritance patterns. Alphanine aids in treating hemophilia by providing clotting factor VIII, which is crucial for controlling bleeding and preventing hemorrhages in individuals with hemophilia A. For example, in November 2022, the United Kingdom Haemophilia Centre Doctors’ Organisation reported that the number of new registrations for Haemophilia A in the UK rose from 16 in 2021 to 19 in 2022. Thus, the growing prevalence of hemophilia will contribute to the growth of the alphanine market.

The increasing awareness of rare diseases is also expected to drive the alphanine market forward. Rare diseases are medical conditions that affect a small portion of the population, often complicating diagnosis, treatment, and access to healthcare. Rising awareness of these diseases is fueled by increased media attention, advocacy efforts, and advancements in diagnostics, which improve early detection and access to specialized care. Alphanine plays a crucial role in this rising awareness by offering a targeted treatment for hemophilia, a rare bleeding disorder, thereby drawing attention to both the disease and the need for effective therapies. For instance, in July 2023, the Department of Health & Social Care estimated that over 7,000 rare diseases exist, with new conditions being discovered as research advances. Around 80% of these diseases are known to have a genetic origin. Therefore, the increasing awareness of rare diseases will continue to drive the growth of the alphanine market.

The growing aging population is expected to further fuel the growth of the alphanine market. An aging population refers to a demographic shift where the proportion of elderly individuals (typically 65 years and older) increases relative to younger age groups. This trend results from advances in healthcare, better living conditions, and medical technologies, which lead to higher life expectancies and lower birth rates. Alphanine is used in the aging population to treat hemophilia and other bleeding disorders by providing clotting factor replacement, preventing or controlling bleeding episodes. For instance, in July 2024, the House of Commons Library reported that individuals aged 65 and older accounted for about 19% of the UK’s population in 2022, or roughly 12.7 million people. By 2072, this group is projected to increase to 22.1 million, making up 27% of the population. Therefore, the growing aging population will drive the expansion of the alphanine market.

The key company operating in the alphanine market is Grifols Biologicals Inc.

North America was the largest region in the alphanine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in alphanine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alphanine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alphanine is a clotting factor concentrate primarily used to treat hemophilia B, a bleeding disorder caused by a deficiency of factor IX. It is a plasma-derived product that helps control and prevent bleeding episodes by replenishing the missing clotting factor in patients with hemophilia B. Alphanine is a highly purified, plasma-derived coagulation factor IX (FIX) concentrate used in the treatment of hemophilia B.

The key formulations in the alphanine market include lyophilized powder and intravenous solutions. Lyophilized powder is a medication form that has been freeze-dried to remove moisture, extending its shelf life and simplifying storage. The various disease indications include hemophilia A, hemophilia B, and hemophilia C, affecting patients of different demographics such as pediatrics, adults, and geriatrics. The distribution channels for Alphanine include hospitals, specialized clinics, retail pharmacies, and mail-order pharmacies.

The alphanine market research report is one of a series of new reports that provides alphanine market statistics, including alphanine industry global market size, regional shares, competitors with an alphanine market share, detailed alphanine market segments, market trends, and opportunities, and any further data you may need to thrive in the alphanine industry. This alphanine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alphanine market consists of sales of Factor IX concentrates, gene therapy solutions, and treatment regimens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.